Analyst Warns Biohaven's Lead Drug May Struggle To Stand Out
Biohaven Ltd. (NYSE: BHVN ) shares fell Monday after Bank of America Securities (BofA) downgraded the biotechnology company, citing an unfavorable risk-reward profile ahead of a key late-stage epilepsy trial. BofA analyst Dina Ramadane downgraded Biohaven to Underperform from Neutral and lowered the price forecast to $